Black Diamond Therapeutics to Present Phase 2 Trial Results on December 3, 2025
- Clinical Trial Update: Black Diamond Therapeutics will present results from its Phase 2 clinical trial of silevertinib during a webcast on December 3, 2025, which may influence investor confidence regarding the company's future developments.
- Therapeutic Innovation: Silevertinib is a fourth-generation EGFR inhibitor targeting EGFR-mutant non-small cell lung cancer and glioblastoma, designed to overcome resistance and minimize toxicity, showcasing the company's cutting-edge position in cancer treatment.
- Information Transparency: The webcast will be accessible via the Investors section of the company's website, with a replay available post-event, ensuring investors can timely access critical clinical data and company updates.
- Market Positioning: Black Diamond Therapeutics focuses on developing therapies targeting genetically defined tumors, indicating its strategy to seek a differentiated competitive advantage in the rapidly evolving oncology market, potentially attracting more investors interested in its innovative treatments.
Trade with 70% Backtested Accuracy
Analyst Views on BDTX
About BDTX
About the author
PayPal Analyst Changes Stance; Check Out Thursday's Top 5 Downgrades
Analyst Downgrades: JP Morgan downgraded Lennar Corporation from Neutral to Underweight, lowering the price target from $118 to $115, while shares closed at $133.13.
EastGroup Properties: Mizuho downgraded EastGroup Properties from Outperform to Neutral, cutting the price target from $180 to $172, with shares closing at $179.24.
Pentair plc: Barclays downgraded Pentair from Overweight to Equal-Weight, slashing the price target from $127 to $115, as shares closed at $106.47.
PayPal Holdings: JP Morgan downgraded PayPal from Overweight to Neutral, reducing the price target from $85 to $70, with shares closing at $61.24.
Black Diamond's Lung Cancer Treatment Demonstrates 60% Response Rate in Phase 2 Results
Phase 2 Trial Results: Black Diamond Therapeutics reported topline data from its Phase 2 trial of silevertinib in non-small cell lung cancer patients, showing a 60% objective response rate and 86% CNS response rate, with no new safety signals observed.
Stock Performance: Following the trial results, BDTX stock experienced a significant decline of 23.77%, trading at $2.62.
Future Plans: The company plans to present updated trial results in 2026 and is also set to initiate a randomized Phase 2 trial for glioblastoma patients in the first half of 2026.
Financial Outlook: Black Diamond has approximately $135.5 million in cash and investments, which it believes will cover operating expenses into the second half of 2028.
US Stocks Show Varied Performance; Dollar Tree Reports Positive Earnings
U.S. Stock Market Performance: U.S. stocks showed mixed results, with the Dow Jones gaining 0.16% while the NASDAQ and S&P 500 fell by 0.42% and 0.07%, respectively. Energy shares rose by 1%, but information technology stocks dropped by 0.9%.
Dollar Tree Earnings Report: Dollar Tree, Inc. reported better-than-expected quarterly results with adjusted earnings per share of $1.21, surpassing the analyst estimate of $1.08, and quarterly sales of $4.746 billion, a 9.4% increase year-over-year.
Significant Stock Movements: Capricor Therapeutics saw a dramatic 441% increase in shares after positive trial results, while CIMG Inc. shares fell 35% following a reverse stock split. Other notable declines included Black Diamond Therapeutics, down 28% after disappointing trial data.
Global Market Trends: European shares mostly rose, with the eurozone's STOXX 600 up 0.2%, while Asian markets closed mixed. Economic indicators showed a decline in the S&P Global services PMI and a slight increase in U.S. industrial production, alongside a job loss of 32,000 in November.
Black Diamond Reports 60% ORR for Silevertinib in NSCLC Patients
- Clinical Trial Results: Silevertinib demonstrated a 60% objective response rate (ORR) in 43 frontline NSCLC patients, with an impressive 86% CNS response rate in those with brain metastases, indicating its potential to redefine treatment standards for non-classical EGFR mutations.
- Future Trial Plans: The company plans to initiate a randomized Phase 2 trial for newly diagnosed glioblastoma (GBM) patients in the first half of 2026, aiming to enroll approximately 150 patients, with preliminary data expected in 2028, showcasing a strong commitment to innovative treatment options.
- Financial Position: As of September 30, 2025, the company reported $135.5 million in cash and equivalents, which is expected to fund operations into the second half of 2028, reflecting solid financial health that supports ongoing research and development.
- Exploration of Partnerships: The company is actively seeking partnership opportunities to advance the pivotal development of Silevertinib, particularly in the NSCLC space, indicating a strategic approach to meet market demands and enhance its competitive position.
Black Diamond Therapeutics Reports 60% ORR for Silevertinib in NSCLC Patients
- Clinical Trial Results: Silevertinib demonstrated a 60% objective response rate (ORR) in 43 frontline NSCLC patients, with an impressive 86% CNS response rate in those with brain metastases, indicating its potential as a significant treatment option for various EGFR mutations.
- Future Trial Plans: The company plans to initiate a randomized Phase 2 trial for newly diagnosed glioblastoma patients in the first half of 2026, aiming to enroll approximately 150 patients, with preliminary data expected in 2028, showcasing a strong commitment to new therapeutic strategies.
- Strong Financial Position: As of September 30, 2025, the company reported $135.5 million in cash and equivalents, which is expected to fund operations into the second half of 2028, ensuring continued investment in R&D and clinical trials.
- Exploration of Partnership Opportunities: Black Diamond is actively seeking partnerships to advance the pivotal development of silevertinib, particularly in the NSCLC space, reflecting the company's keen insight into market demands and strategic positioning.
Black Diamond to Showcase Phase 2 Results of Silevertinib for Non-Small Cell Lung Cancer Today
Webcast Presentation: Black Diamond Therapeutics will host a webcast on December 3, 2025, to present results from its Phase 2 trial of silevertinib in non-small cell lung cancer (NSCLC) patients with non-classical EGFR mutations, including objective response rates and treatment duration data from 43 patients.
Clinical Trial Progress: Silevertinib is being evaluated in three clinical settings: first-line NSCLC, second/third-line NSCLC in C797S+ patients, and glioblastoma, with key data expected in the first half of 2026.
FDA Designation: The second/third-line NSCLC study has received FDA Fast Track designation, highlighting its potential to meet significant medical needs, while the company plans to seek FDA feedback on registration for the first-line NSCLC trial.
Financial Status: As of the end of Q3 2025, Black Diamond Therapeutics reported $135.5 million in cash and investments, projected to fund operations through Q4 2027, despite a recent stock price decline to $3.45.
PayPal Analyst Changes Stance; Check Out Thursday's Top 5 Downgrades
Analyst Downgrades: JP Morgan downgraded Lennar Corporation from Neutral to Underweight, lowering the price target from $118 to $115, while shares closed at $133.13.
EastGroup Properties: Mizuho downgraded EastGroup Properties from Outperform to Neutral, cutting the price target from $180 to $172, with shares closing at $179.24.
Pentair plc: Barclays downgraded Pentair from Overweight to Equal-Weight, slashing the price target from $127 to $115, as shares closed at $106.47.
PayPal Holdings: JP Morgan downgraded PayPal from Overweight to Neutral, reducing the price target from $85 to $70, with shares closing at $61.24.
Black Diamond's Lung Cancer Treatment Demonstrates 60% Response Rate in Phase 2 Results
Phase 2 Trial Results: Black Diamond Therapeutics reported topline data from its Phase 2 trial of silevertinib in non-small cell lung cancer patients, showing a 60% objective response rate and 86% CNS response rate, with no new safety signals observed.
Stock Performance: Following the trial results, BDTX stock experienced a significant decline of 23.77%, trading at $2.62.
Future Plans: The company plans to present updated trial results in 2026 and is also set to initiate a randomized Phase 2 trial for glioblastoma patients in the first half of 2026.
Financial Outlook: Black Diamond has approximately $135.5 million in cash and investments, which it believes will cover operating expenses into the second half of 2028.
US Stocks Show Varied Performance; Dollar Tree Reports Positive Earnings
U.S. Stock Market Performance: U.S. stocks showed mixed results, with the Dow Jones gaining 0.16% while the NASDAQ and S&P 500 fell by 0.42% and 0.07%, respectively. Energy shares rose by 1%, but information technology stocks dropped by 0.9%.
Dollar Tree Earnings Report: Dollar Tree, Inc. reported better-than-expected quarterly results with adjusted earnings per share of $1.21, surpassing the analyst estimate of $1.08, and quarterly sales of $4.746 billion, a 9.4% increase year-over-year.
Significant Stock Movements: Capricor Therapeutics saw a dramatic 441% increase in shares after positive trial results, while CIMG Inc. shares fell 35% following a reverse stock split. Other notable declines included Black Diamond Therapeutics, down 28% after disappointing trial data.
Global Market Trends: European shares mostly rose, with the eurozone's STOXX 600 up 0.2%, while Asian markets closed mixed. Economic indicators showed a decline in the S&P Global services PMI and a slight increase in U.S. industrial production, alongside a job loss of 32,000 in November.
Black Diamond Reports 60% ORR for Silevertinib in NSCLC Patients
- Clinical Trial Results: Silevertinib demonstrated a 60% objective response rate (ORR) in 43 frontline NSCLC patients, with an impressive 86% CNS response rate in those with brain metastases, indicating its potential to redefine treatment standards for non-classical EGFR mutations.
- Future Trial Plans: The company plans to initiate a randomized Phase 2 trial for newly diagnosed glioblastoma (GBM) patients in the first half of 2026, aiming to enroll approximately 150 patients, with preliminary data expected in 2028, showcasing a strong commitment to innovative treatment options.
- Financial Position: As of September 30, 2025, the company reported $135.5 million in cash and equivalents, which is expected to fund operations into the second half of 2028, reflecting solid financial health that supports ongoing research and development.
- Exploration of Partnerships: The company is actively seeking partnership opportunities to advance the pivotal development of Silevertinib, particularly in the NSCLC space, indicating a strategic approach to meet market demands and enhance its competitive position.
Black Diamond Therapeutics Reports 60% ORR for Silevertinib in NSCLC Patients
- Clinical Trial Results: Silevertinib demonstrated a 60% objective response rate (ORR) in 43 frontline NSCLC patients, with an impressive 86% CNS response rate in those with brain metastases, indicating its potential as a significant treatment option for various EGFR mutations.
- Future Trial Plans: The company plans to initiate a randomized Phase 2 trial for newly diagnosed glioblastoma patients in the first half of 2026, aiming to enroll approximately 150 patients, with preliminary data expected in 2028, showcasing a strong commitment to new therapeutic strategies.
- Strong Financial Position: As of September 30, 2025, the company reported $135.5 million in cash and equivalents, which is expected to fund operations into the second half of 2028, ensuring continued investment in R&D and clinical trials.
- Exploration of Partnership Opportunities: Black Diamond is actively seeking partnerships to advance the pivotal development of silevertinib, particularly in the NSCLC space, reflecting the company's keen insight into market demands and strategic positioning.
Black Diamond to Showcase Phase 2 Results of Silevertinib for Non-Small Cell Lung Cancer Today
Webcast Presentation: Black Diamond Therapeutics will host a webcast on December 3, 2025, to present results from its Phase 2 trial of silevertinib in non-small cell lung cancer (NSCLC) patients with non-classical EGFR mutations, including objective response rates and treatment duration data from 43 patients.
Clinical Trial Progress: Silevertinib is being evaluated in three clinical settings: first-line NSCLC, second/third-line NSCLC in C797S+ patients, and glioblastoma, with key data expected in the first half of 2026.
FDA Designation: The second/third-line NSCLC study has received FDA Fast Track designation, highlighting its potential to meet significant medical needs, while the company plans to seek FDA feedback on registration for the first-line NSCLC trial.
Financial Status: As of the end of Q3 2025, Black Diamond Therapeutics reported $135.5 million in cash and investments, projected to fund operations through Q4 2027, despite a recent stock price decline to $3.45.
